Leticia Uwedjojevwe
Internal Medicine · Chula Vista, CANPI 1891882221
Payments from drug & device makers
Across 741 payments — averaging $17.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- AstraZeneca$1K
- Novo Nordisk$983
- Lilly USA, LLC$913
- AbbVie$734
- Novartis$704
- plus $7K from 41 others
What the payments were for
- Travel & lodging$80%
- Food & beverage$12,77099%
- Education$1131%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GEMTESA$218
- TRELEGY ELLIPTA$124
- Ozempic$121
- AIMOVIG$120
- AJOVY$114
How this compares
$12,891 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 524 | $423,662 |
| TymlosAbaloparatide | 70 | $215,462 |
| OzempicSemaglutide | 174 | $205,164 |
| EliquisApixaban | 149 | $122,983 |
| KerendiaFinerenone | 130 | $100,159 |
| TrulicityDulaglutide | 82 | $99,887 |
| Repatha SureclickEvolocumab | 96 | $74,275 |
| JanuviaSitagliptin Phosphate | 65 | $62,505 |
| ProliaDenosumab | 31 | $53,497 |
| RybelsusSemaglutide | 40 | $48,896 |
| GemtesaVibegron | 66 | $46,490 |
| LinzessLinaclotide | 66 | $45,100 |
| FarxigaDapagliflozin Propanediol | 59 | $45,090 |
| EntrestoSacubitril/Valsartan | 50 | $41,849 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 44 | $34,450 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $446 | $423,662524 claims |
| Novo NordiskOzempic, Rybelsus | $983 | $254,059214 claims |
| Radius Health, Inc.Tymlos | $505 | $215,46270 claims |
| PfizerEliquis | $292 | $122,983149 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $913 | $120,74296 claims |
| BayerKerendia | $611 | $100,159130 claims |
| MerckJanuvia, Janumet | $85 | $85,17486 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,027 | $56,33975 claims |
| AmgenProlia | $1,708 | $53,49731 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $550 | $46,49066 claims |
| AbbVieLinzess | $734 | $45,10066 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $662 | $44,48868 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Chula Vista
- Andrew ChengSouth San Francisco$55.1M
- Joel NeutelTustin$34.9M
- Donald BrandonSan Diego$34M
- William TownerLos Angeles$27.4M
- Rahul AggarwalSan Francisco$24M
- Masoud AzizadNorthridge$21.1M
- Helen StaceyWalnut Creek$20.4M
- Rohit Loombala Jolla$15.1M
- Zeid KayaliColton$14.2M
- Alexandra DrakakiSanta Monica$14.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.